Blenrep (belantamab mafodotin) combination accepted for priority review in China in R/R multiple myeloma December 10, 2024
Blenrep combinations accepted for review by the FDA for the treatment of R/R multiple myeloma November 26, 2024
Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myeloma November 15, 2024
Ph 1 and iMMagine-1 studies of anito-cel in R/R multiple myeloma patients continue to demonstrate durability and a manageable safety profile November 13, 2024
Applications submitted in the U.S. and EU seeking approval of DARZALEX FASPRO / DARZALEX as SC monotherapy for high-risk smoldering multiple myeloma November 12, 2024
Orphan Drug Designation from the US FDA for LBL-034 for the Treatment of Multiple Myeloma November 12, 2024
DARZALEX® (daratumumab)-SC based quadruplet regimen approved by the EC for patients with newly diagnosed multiple myeloma who are transplant-eligible October 29, 2024
Poseida Therapeutics Announces Nomination of New CAR-T Development Candidate Under Collaboration with Roche October 22, 2024
Type II variation application to the EMA for DARZALEX® (daratumumab) SC-based quadruplet regimen for newly diagnosed multiple myeloma patients October 15, 2024
Ph 1 results for Ribrecabtagene autoleucel (DRL-1801) from the SWASTH study in patients with R/R multiple myeloma announced October 15, 2024
Positive Interim Ph 1 Results for P-BCMA-ALLO1 with High ORR in Heavily Pretreated RRMM Patients Reported October 8, 2024
Supplemental BLA filed for U.S. FDA approval of DARZALEX FASPRO®-based quadruplet regimen for newly diagnosed multiple myeloma patients for whom transplant is not planned October 8, 2024
CARVYKTI significantly extends OS vs standard therapies for patients with multiple myeloma as early as second line October 2, 2024
Enrollment discontinued in Ph 3 KarMMa-9 study of Abecma with lenalidomide maintenance in newly diagnosed multiple myeloma (NDMM) patients with suboptimal response after autoSCT October 2, 2024
DARZALEX FASPRO-based quadruplet regimen significantly improves MRD negativity for newly diagnosed multiple myeloma patients for whom transplant is not planned October 1, 2024
TALVEY® (talquetamab-tgvs) and TECVAYLI® (teclistamab-cqyv) combo yields high response rates and durable responses in triple-class refractory RRMM patients October 1, 2024
Blenrep (belantamab mafodotin) combinations in R/R multiple myeloma accepted for regulatory review in Japan September 24, 2024
Blenrep (belantamab mafodotin) combination receives Breakthrough Therapy Designation in China in R/R multiple myeloma September 24, 2024
DARZALEX® (daratumumab)-based quadruplet regimen receives positive CHMP opinion for transplant-eligible patients with newly diagnosed multiple myeloma September 24, 2024
Sarclisa + SOC approved in the US for adult patients with newly diagnosed multiple myeloma not eligible for transplant September 24, 2024
FDA approves BORUZU, a new presentation of bortezomib for ready-to-use subcutaneous administration or IV administration September 10, 2024
New Case Study Demonstrating Reactivation of P-BCMA-101 CAR-T Therapy with a T-Cell Engager in a Patient with Relapsed Multiple Myeloma Presented September 10, 2024
